---
title: "阿斯利康第二款 ADC 药物在国内获批用于乳腺癌"
description: "阿斯利康宣布其第二款 ADC 药物德达博妥单抗（达卓优）已在中国获批，用于治疗特定类型的晚期乳腺癌患者。该药物适用于曾接受内分泌治疗并经历至少一线化疗的不可切除或转移性激素受体阳性、HER2 阴性乳腺癌成人患者。德达博妥单抗是一种靶向 TROP2 的抗体偶联药物，由阿斯利康与第一三共合作开发。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/254176767.md"
published_at: "2025-08-22T12:38:10.000Z"
---

# 阿斯利康第二款 ADC 药物在国内获批用于乳腺癌

> 阿斯利康宣布其第二款 ADC 药物德达博妥单抗（达卓优）已在中国获批，用于治疗特定类型的晚期乳腺癌患者。该药物适用于曾接受内分泌治疗并经历至少一线化疗的不可切除或转移性激素受体阳性、HER2 阴性乳腺癌成人患者。德达博妥单抗是一种靶向 TROP2 的抗体偶联药物，由阿斯利康与第一三共合作开发。

阿斯利康宣布，注射用德达博妥单抗（达卓优）正式在国内获批，用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体（HR）阳性、人类表皮生长因子受体 2（HER2）阴性乳腺癌成人患者。 德达博妥单抗是一款靶向 TROP2 抗体偶联药物 (ADC)，是阿斯利康和第一三共合作开发并引入中国的第二款 ADC 药物。（澎湃）

### Related Stocks

- [AZN.US - 阿斯利康](https://longbridge.com/zh-CN/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power | AstraZeneca has reached a drug-pricing deal with President Trump to reduce Medicaid drug prices, potentially reshaping B | [Link](https://longbridge.com/zh-CN/news/260941568.md) |
| ANALYSIS-AstraZeneca's US listing may pull other firms from London in its wake | AstraZeneca's decision to upgrade its U.S. listing while retaining its London presence may influence other UK firms to c | [Link](https://longbridge.com/zh-CN/news/259563996.md) |
| Advance Auto Parts’ Heavy Debt Load Raises Liquidity, Refinancing and Turnaround Risks | Advance Auto Parts Inc (AAP) is facing significant financial risks due to its heavy debt load, which may limit liquidity | [Link](https://longbridge.com/zh-CN/news/275997122.md) |
| Did Analyst Upgrades and Metal Price Tailwinds Just Shift Coeur Mining's (CDE) Investment Narrative? | Recent analyst upgrades for Coeur Mining, alongside rising gold and silver prices, have shifted focus on the company's c | [Link](https://longbridge.com/zh-CN/news/275995095.md) |
| Angi (ANGI) Valuation Check After Weak Q4 Results And Sharp Share Price Drop | Angi (ANGI) reported a 10.1% year-on-year revenue decline in Q4 2025, leading to a significant drop in share price. Desp | [Link](https://longbridge.com/zh-CN/news/275986898.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。